TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8267066
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of oral slow‐release isradipine twice a day
Study: 8267066
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of methyldopa three times a day
Study: 8267066
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of oral slow‐release isradipine twice a day
Study: 8267066
Drug: Matched controls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched controls without medication
Study: 3749828
Drug: Lidocaine 1%
Normalized name: LIDOCAINE 1% LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1% (2 ml)
Study: 3749828
Drug: Diclofenac (Voltaren)
Normalized name: diclofenac Topical Gel [Voltaren]
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac (Voltaren) (50 mg, 2 ml)
Study: 28801938
Drug: Gabapentin 1500
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1500 mg/day
Study: 8750483
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) for at least one year
Study: 27893032
Drug: Individual Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Cognitive Processing Therapy (CPT) - 60-minute sessions, twice weekly for 6 weeks
Study: 27893032
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Processing Therapy (CPT) - 90-minute sessions, twice weekly for 6 weeks
Study: 17389458
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) therapy, mean dose 0.16±0.06 mg/day
Study: 2001087
Drug: Propafenone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (300 mg three times daily in 19 patients, 300 mg twice daily in 3 patients, and 150 mg twice daily in 1 patient)
Study: 6340806
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% eye drops after placebo or 80 mg propranolol
Study: 6340806
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% eye drops after 160 mg propranolol
Study: 6340806
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% eye drops after 120 mg propranolol
Study: 30817752
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for child SepAD (TAFF or CC)
Study: 11215748
Drug: Octreotide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (0.1 mg subcutaneously three times a day)
Study: 11215748
Drug: Control (conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conservative treatment only)
Study: 8628802
Drug: Smooth-walled implants
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smooth-walled implants
Study: 1728731
Drug: Early antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early antibiotics (2 to 24 hours before incision)
Study: 6142643
Drug: diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 10 mg in its commercially available form
Study: 6142643
Drug: diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam 10 mg masked in opaque capsules
Study: 6142643
Drug: hydroxyzine pamoate
Normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydroxyzine pamoate 50 mg in its commercially available form
Study: 6142643
Drug: hydroxyzine pamoate
Normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydroxyzine pamoate 50 mg masked in opaque capsules
Study: 6142643
Drug: previous drug
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: previous drug therapy
Study: 15660075
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg po preoperatively and Dexamethasone 10 mg IV intraoperatively
Study: 15660075
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg po preoperatively
Study: 15660075
Drug: Placebo po
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo po preoperatively and Dexamethasone 10 mg IV intraoperatively
Study: 10100362
Drug: Irrigating fluids
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigating fluids containing glycine, mannitol, and sorbitol infused at 0.75 ml/kg/min for 20 min
Study: 2238575
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIG) therapy
Study: 17001071
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg) administered monthly for 3 months
Study: 15253688
Drug: Alefacept (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alefacept (12 weekly injections followed by 12 treatment-free weeks)
Study: 30249211
Drug: Combination nivolumab/ipilimumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination nivolumab/ipilimumab
Study: 30249211
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care neoadjuvant radiation therapy
Study: 26147943
Drug: Evidence supported
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence supported smoking cessation therapy (including pharmacotherapy and behavioral support)
Study: 21218747
Drug: Intravenous omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous omeprazole (initial dose of 80 mg, followed by 8 mg/h infusion)
Study: 21218747
Drug: Intravenous ranitidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ranitidine (100 mg bolus, followed by 100 mg boluses every 6 hours for 72 hours)
Study: 18523394
Drug: Radiographic esophageal
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiographic esophageal imaging by oral administration of contrast media
Study: 15926017
Drug: Amitriptyline 10
Normalized name: amitriptyline 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 10 mg daily for two months
Study: 15926017
Drug: Intra-oral device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-oral device appliance for two months
Study: 10340911
Drug: Terbinafine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine (250 mg once daily for 14 days)
Study: 1775605
Drug: Arecoline at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline at 4 mg/day
Study: 399858
Drug: Salbutamol dry
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol dry powder (200 micrograms per capsule)
Study: 399858
Drug: Rotahaler (device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotahaler (device for powder administration)
Study: 19917927
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by concurrent chemoradiotherapy (CRT)
Study: 11277642
Drug: Carboplatin alone
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin alone (300 mg/m2 every 28 days for five cycles)
Study: 11277642
Drug: Carboplatin plus
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin plus epidoxorubicin (120 mg/m2 and 300 mg/m2 every 28 days for five cycles)
Study: 8371471
Drug: Beta-blockers (class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (class II agents)
Study: 8371471
Drug: Amiodarone (class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (class III agent)
Study: 8371471
Drug: Class IV
Normalized name: Class IV antiarrhythmic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class IV agents (calcium channel blockers)
Study: 9209898
Drug: Vaginal estriol
Normalized name: estriol Vaginal Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal estriol (0.5 mg daily)
Study: 9209898
Drug: 17 beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta‐estradiol (0.05 mg daily)
Study: 8272550
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (CDP, 2 cycles) followed by radical surgery
Study: 3040605
Drug: Enalapril (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5-10 mg twice daily)
Study: 29302858
Drug: Eribulin mesilate
Normalized name: Eribulin mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin mesilate 1.4 mg/m2 intravenously on days 1 and 8
Study: 29302858
Drug: Capecitabine 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine 1.25 g/m2 orally twice daily on days 1-14 (21-day cycles)
Study: 24584818
Drug: Spouse-assisted lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spouse-assisted lifestyle intervention (9 monthly telephone calls to patients and spouses)
Study: 20507841
Drug: Diclofenac 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 3% gel treatment
Study: 18826094
Drug: Sonographically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonographically guided percutaneous ethanol injection (4 injections on average in the first group, 6 injections in the second group, 2-10 ml ethanol per injection)
Study: 18826094
Drug: Sonographically guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonographically guided percutaneous ethanol injection (6 injections)
Study: 15975536
Drug: 7-day triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day triple therapy with esomeprazole 20mg b.i.d., clarithromycin 500 mg b.i.d. and amoxycillin 1g b.i.d.
Study: 15975536
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy comprising of the same regimen plus lactoferrin 200mg b.i.d.
Study: 9249934
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (tacrolimus 0.10 mg/kg and prednisolone)
Study: 9249934
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (tacrolimus 0.06 mg/kg, prednisolone, and azathioprine)
Study: 8388030
Drug: Alpha-interferon preparations
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpha-interferon preparations (exact dosage and duration not specified)
Study: 28579233
Drug: Vaccine with
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine with 120μg RSV F protein and 0.4mg aluminum
Study: 28579233
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of 60μg RSV F protein and 0.8mg aluminum
Study: 28579233
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations (including placebo)
Study: 25647729
Drug: Nonoxynol-9 2%
Normalized name: NONOXYNOL-9 2% GEL,VAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol-9 2% gel
Study: 24127924
Drug: Hydrogen-rich water
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich water (HRW) 1200-1800 mL/day, twice daily for 6 weeks
Study: 18081359
Drug: hylan G‐F
Approvals — FDA: no, EMA: no, PMDA: no
Description: hylan G‐F 20
Study: 10661482
Drug: rhEPO therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO therapy
Study: 10661482
Drug: No rhEPO
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rhEPO therapy
Study: 10661482
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (10 mg, 3 times a week)
Study: 10661482
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of controls and dialyzed patients on rhEPO therapy
Study: 23452711
Drug: Emotional Freedom
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotional Freedom Technique (EFT), used twice a day for two months
Study: 18848470
Drug: 1500 mg
Normalized name: inulin 1500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500 mg of oral glucosamine sulphate once daily for 2 years
Study: 18848470
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 2 years
Study: 17128343
Drug: Single-dose tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose tinidazole plus fluconazole (TF)
Study: 17128343
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with metronidazole plus vaginal clotrimazole (MC)
Study: 17128343
Drug: Single-dose tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose tinidazole plus fluconazole (TF) among HIV-infected women
Study: 17128343
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with metronidazole plus vaginal clotrimazole (MC) among HIV-infected women
Study: 17128343
Drug: Single-dose tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose tinidazole plus fluconazole (TF) among HIV-uninfected women
Study: 17128343
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with metronidazole plus vaginal clotrimazole (MC) among HIV-uninfected women
Study: 17128343
Drug: Single-dose tinidazole
Normalized name: Tinidazole
DrugBank: Tinidazole (DB00911)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose tinidazole plus fluconazole (TF) followed by metronidazole plus vaginal clotrimazole (MC) as second-line treatment
Study: 11721720
Drug: Intravenous diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diltiazem (10 mg bolus + 10 mg/hour for 3 days)
Study: 8256988
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1700 mg of calcium carbonate daily)
Study: 8256988
Drug: Estrogen-progesterone-calcium (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-progesterone-calcium (0.625 mg conjugated equine estrogens, 10 mg progesterone, and 1700 mg elemental calcium daily)
Study: 3300974
Drug: isosorbide 5‐mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: isosorbide 5‐mononitrate (acute administration)
Study: 3300974
Drug: isosorbide 5‐mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: isosorbide 5‐mononitrate (2 months treatment, 20 mg three times daily)
Study: 3300974
Drug: placebo (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (acute administration)
Study: 31914620
Drug: Exercise twice-a-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise twice-a-day
Study: 31914620
Drug: Once-daily exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily exercise
Study: 16681817
Drug: Luliconazole 1%
Normalized name: LULICONAZOLE 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luliconazole 1% cream applied once a day for 2 weeks, followed by placebo for 2 weeks.
Study: 16681817
Drug: Bifonazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole 1% cream applied once a day for 4 weeks.
Study: 16681817
Drug: Luliconazole 1%
Normalized name: LULICONAZOLE 1% CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luliconazole 1% cream
Study: 24684520
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (8-week treatment as an adjunct to usual psoriasis therapy)
Study: 24684520
Drug: Usual psoriasis
Normalized name: MG 217 Psoriasis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual psoriasis therapy alone (Control group)
Study: 23427387
Drug: Jiutengzhuyu tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jiutengzhuyu tablets taken orally for 25 days
Study: 23427387
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine infusion of 5 mg dexamethasone sodium phosphate, 4000 units of chymotrypsin, 80,000 units of gentamicin sulfate in 20 mL normal saline at 1 mL/min
Study: 19155999
Drug: Paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (100 mg/m(2) d(1), d(8), d(15)) plus gemcitabine (1250 mg/m(2) d(1) and d(8), every 4 weeks) - Arm B
Study: 19155999
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m(2), d(1)) and gemcitabine (1250 mg/m(2), d(1) and d(8), every 3 weeks) - Arm A
Study: 11822009
Drug: Expandable metal
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expandable metal stents or ablative therapy
Study: 9846778
Drug: Gabapentin (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (maximum dosage of 3600 mg/d)
Study: 24593836
Drug: Supragingival scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supragingival scaling treatment
Study: 22172433
Drug: LibiGel (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: LibiGel (low-dose testosterone gel)
Study: 20823282
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg twice daily (arm A)
Study: 20823282
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg plus atazanavir 400 mg once daily (arm B)
Study: 16395096
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (2 doses, 6-8 weeks apart)
Study: 16395096
Drug: MMR+V group
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMR+V group (1 dose of MMR and 1 dose of varicella, followed by a second dose of MMR at 6-8 weeks later)
Study: 16395096
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (after first dose)
Study: 16395096
Drug: MMR+V group
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMR+V group (after first dose)
Study: 16395096
Drug: MMRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMRV vaccine (after second dose)
Study: 16395096
Drug: MMR+V group
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMR+V group (after second dose)
Study: 8622612
Drug: Intravenous endothelin-1
Normalized name: nitric oxide synthase endothelial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous endothelin-1
Study: 8622612
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (10 mg) pretreatment before endothelin-1 infusion
Study: 26319955
Drug: Peppermint oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil (PO) 3 times daily for 4 weeks
Study: 26319955
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 times daily for 4 weeks
Study: 25694037
Drug: MK-7 (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7 (180 µg MenaQ7/day)
Study: 15696079
Drug: Zafirlukast, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast, 80 mg twice daily for 6 weeks
Study: 12854927
Drug: Dinoprostone vaginal
Normalized name: dinoprostone Vaginal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone vaginal insert (10 mg every 12 h for a maximum of 24 h)
Study: 10543411
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glibenclamide
Study: 8911107
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy regimen (CTC) incorporating cyclophosphamide, thiotepa, and carboplatin with autologous PBSC support.
Study: 8911107
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy regimen (CTC) with autologous PBSC support.
Study: 26707418
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (Travoprost 0.004%)
Study: 24754066
Drug: Adequate eradication
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate eradication therapy during treatment for CHD
Study: 24754066
Drug: Antisecretory therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisecretory therapy
Study: 24754066
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for CHD only
Study: 10169531
Drug: Zileuton 600
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 600 mg QID
Study: 10169531
Drug: Zileuton 600
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 600 or 800 mg TID
Study: 10169531
Drug: Zileuton 600
Normalized name: zileuton 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zileuton 600 or 800 mg BID
Study: 29164421
Drug: Ribociclib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib (600 mg/day; 3 weeks-on/1 week-off) plus letrozole (2.5 mg/day; continuous)
Study: 29164421
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus letrozole (2.5 mg/day; continuous)
Study: 26408375
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptives (COCs) with doxycycline 40 mg